

## Summary of risk management plan for Claversal 500 mg gastro-resistant tablets.

This is a summary of the risk management plan (RMP) for Claversal 500 mg gastro-resistant tablets. The RMP details important risks of Claversal 500 mg gastro-resistant tablets, how these risks can be minimised, and how more information will be obtained about Claversal 500 mg gastro-resistant tablets' risks and uncertainties (missing information).

Claversal 500 mg gastro-resistant tablets' summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how Claversal 500 mg gastro-resistant tablets should be used.

### **I. The medicine and what it is used for**

Claversal 500 mg gastro-resistant tablets is authorised for the treatment of the acute phase of mild or moderate ulcerative colitis; the maintenance treatment of remission in ulcerative colitis (including patients unable to tolerate salazosulphapyridine) and for the treatment of acute episodes and the maintenance of remission of Crohn's disease. (see SmPC for the full indication). It contains mesalazine as the active substance and it is given by oral route.

### **II. Risks associated with the medicine and activities to minimise or further characterise the risks**

Important risks of Claversal 500 mg gastro-resistant tablets, together with measures to minimise such risks and the proposed studies for learning more about Claversal 500 mg gastro-resistant tablets' risks, are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine's packaging;
- The authorised pack size — the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status — the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimise its risks.

Together, these measures constitute *routine risk minimisation* measures.

In addition to these measures, information about adverse reactions is collected continuously and regularly analysed, including PSUR assessment so that immediate action can be taken as necessary. These measures constitute routine pharmacovigilance activities.

If important information that may affect the safe use of Claversal 500 mg gastro-resistant tablets is not yet available, it is listed under 'missing information' below.

#### **II.A List of important risks and missing information**

Important risks of Claversal 500 mg gastro-resistant tablets are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely administered. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of Claversal 500 mg gastro-resistant tablets.

Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine);

<b>List of important risks and missing information</b>	
Important identified risks	None
Important potential risks	None
Missing information	None

## **II.B Summary of important risks**

Not applicable.

## **II.C Post-authorisation development plan**

### ***II.C.1 Studies which are conditions of the marketing authorisation***

There are no studies which are conditions of the marketing authorisation or specific obligation of Claversal 500 mg gastro-resistant tablets.

### ***II.C.2 Other studies in post-authorisation development plan***

There are no studies required for Claversal 500 mg gastro-resistant tablets.